Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Niclosamide | 1 | 2023 | 3 | 0.850 |
Why?
|
| Endometrial Neoplasms | 2 | 2023 | 187 | 0.820 |
Why?
|
| Benzopyrans | 5 | 2013 | 17 | 0.770 |
Why?
|
| Piperidines | 4 | 2013 | 45 | 0.590 |
Why?
|
| Apoptosis | 5 | 2023 | 738 | 0.570 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 30 | 0.540 |
Why?
|
| Endometrial Hyperplasia | 1 | 2015 | 6 | 0.510 |
Why?
|
| Gallbladder Neoplasms | 1 | 2016 | 14 | 0.510 |
Why?
|
| Antineoplastic Agents | 7 | 2017 | 657 | 0.450 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 377 | 0.440 |
Why?
|
| MicroRNAs | 1 | 2016 | 279 | 0.390 |
Why?
|
| Hyperplasia | 1 | 2011 | 27 | 0.370 |
Why?
|
| Uterus | 1 | 2011 | 31 | 0.370 |
Why?
|
| Chromans | 3 | 2023 | 59 | 0.330 |
Why?
|
| Neoplasms | 1 | 2016 | 767 | 0.290 |
Why?
|
| Cyclin D1 | 3 | 2023 | 38 | 0.280 |
Why?
|
| Thiones | 2 | 2017 | 55 | 0.280 |
Why?
|
| Cell Proliferation | 6 | 2023 | 773 | 0.270 |
Why?
|
| Risk Factors | 3 | 2016 | 2036 | 0.270 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 1268 | 0.250 |
Why?
|
| Animals | 9 | 2023 | 10067 | 0.240 |
Why?
|
| Receptors, Estrogen | 3 | 2014 | 42 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2023 | 154 | 0.220 |
Why?
|
| Breast Neoplasms | 4 | 2013 | 446 | 0.220 |
Why?
|
| Cathepsin B | 1 | 2023 | 4 | 0.210 |
Why?
|
| ErbB Receptors | 2 | 2013 | 96 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 665 | 0.210 |
Why?
|
| Female | 10 | 2023 | 14631 | 0.210 |
Why?
|
| Lysosomes | 1 | 2023 | 55 | 0.210 |
Why?
|
| Humans | 14 | 2023 | 27139 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2015 | 398 | 0.190 |
Why?
|
| Reactive Oxygen Species | 2 | 2012 | 279 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2014 | 1374 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 312 | 0.170 |
Why?
|
| Suppositories | 1 | 2017 | 7 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 566 | 0.140 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 35 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 163 | 0.130 |
Why?
|
| Progesterone Congeners | 1 | 2015 | 4 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2015 | 31 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 37 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 26 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 250 | 0.130 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 7 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 444 | 0.130 |
Why?
|
| Adult Stem Cells | 1 | 2015 | 10 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2016 | 229 | 0.120 |
Why?
|
| Hysterectomy | 1 | 2015 | 85 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 85 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 472 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 25 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 126 | 0.120 |
Why?
|
| Aniline Compounds | 1 | 2014 | 23 | 0.120 |
Why?
|
| Hyaluronic Acid | 1 | 2015 | 95 | 0.120 |
Why?
|
| Telomerase | 1 | 2014 | 37 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 544 | 0.110 |
Why?
|
| Disease Progression | 1 | 2015 | 458 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 438 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 98 | 0.110 |
Why?
|
| Phenotype | 1 | 2016 | 666 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 762 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 30 | 0.110 |
Why?
|
| Mice | 6 | 2023 | 4466 | 0.110 |
Why?
|
| Catechin | 1 | 2012 | 13 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 45 | 0.100 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2012 | 5 | 0.100 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2012 | 8 | 0.100 |
Why?
|
| RANK Ligand | 1 | 2012 | 19 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 33 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 44 | 0.100 |
Why?
|
| Osteoclasts | 1 | 2012 | 28 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 35 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 270 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 287 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 538 | 0.080 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2009 | 8 | 0.080 |
Why?
|
| Pyrones | 1 | 2009 | 6 | 0.080 |
Why?
|
| Rats | 1 | 2011 | 1544 | 0.070 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 216 | 0.060 |
Why?
|
| Heterografts | 1 | 2023 | 62 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 2 | 2013 | 26 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 86 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 264 | 0.050 |
Why?
|
| Cell Survival | 2 | 2013 | 394 | 0.050 |
Why?
|
| Food, Formulated | 1 | 2017 | 11 | 0.040 |
Why?
|
| Emulsifying Agents | 1 | 2017 | 7 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 29 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2017 | 12 | 0.040 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2017 | 26 | 0.040 |
Why?
|
| Biological Availability | 1 | 2017 | 43 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2017 | 166 | 0.040 |
Why?
|
| Hemangioblasts | 1 | 2015 | 2 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 17 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2015 | 75 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 62 | 0.030 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2013 | 4 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 464 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2013 | 5 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2013 | 62 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 23 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 33 | 0.030 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 13 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 26 | 0.030 |
Why?
|
| Neurons | 1 | 2015 | 274 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2013 | 47 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 1494 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 134 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 2012 | 6 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2012 | 57 | 0.030 |
Why?
|
| Gastrins | 1 | 2012 | 28 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2012 | 36 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2012 | 197 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 333 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 187 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 679 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2009 | 16 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 35 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 2009 | 11 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 102 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 627 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 239 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2009 | 445 | 0.020 |
Why?
|
| Aged | 1 | 2013 | 5222 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 7496 | 0.010 |
Why?
|
| Middle Aged | 1 | 2013 | 6906 | 0.010 |
Why?
|
| Male | 1 | 2014 | 13014 | 0.010 |
Why?
|